Variational AI is excited to participate in the inaugural AI Convergence: Small Molecule Discovery Summit in Boston, bringing together leaders at the intersection of AI/ML, computational chemistry, and medicinal chemistry. This is a great venue to compare notes on how generative approaches are being applied to real-world small-molecule design workflows (from hit expansion to multiparameter lead optimization).
Our CEO, Handol Kim, will be speaking at the event.
Quality Over Quantity: Rethinking AI-Driven Drug Discovery
Is Bigger Always Better? Training AI/ML Models with Low Volume Datasets to Generate Molecular Chemistry with Desired Preclinical Target Product Profiles & Physiochemical Properties
Handol will be available during the summit for conversations with pharma/biotech teams exploring AI-enabled small-molecule discovery. To schedule time, reach out to bd@variational.ai.